with Judge Greene that Winther's prospects for rehabilitation were better than average. In support of this finding, the panel concluded:
(a) Winther is aware of and accepts his guilt, (b) Winther does not shift the blame to the child, (c) Winther made early efforts to get counseling and sincerely participated in counseling before and after incarceration, (d) Winther cares for his children, and (e) the psychological reports indicate that his prognosis for rehabilitation is good.
The panel, with Judge Gonzalez dissenting, concluded, however, that Winther should receive the eight-year presumptive term. In reaching its conclusion, the panel relied on the following negative factors:
(a) Winther is a highly manipulative person, (b) Winther's abuse of his young daughter occurred over a long period of time, (c) Winther has significant psychological problems whichFaraday, and personal fees from W.L. Gore, outside the submitted work;

Ulf Dahlstrӧm: reports grants from AstraZeneca, other from Novartis, and other from AstraZeneca, outside the submitted work;

Aldo P. Maggioni: reports personal fees from Bayer, personal fees from Novartis, and personal fees from Fresenius, outside the submitted work.

Luigi Tavazzi: reports personal fees from Servier and personal fees from CVie Therapeutics, outside the submitted work.

Funding {#ehf212537-sec-0017}
=======

Since the start of EORP, the following companies have supported the programme: Abbott Vascular International (2011--2021), Amgen Cardiovascular (2009--2018), AstraZeneca (2014--2021), Bayer AG (2009--2018), Boehringer Ingelheim (2009--2019), Boston Scientific (2009--2012), The Bristol Myers Squibb and Pfizer Alliance (2011--2019), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011--2017), Daiichi Sankyo Europe (2012--2020), Edwards (2016--2019), Gedeon Richter plc (2014--2017), Menarini International Op. (2009--2012), MSD--Merck